Yoshiaki Tanji

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Toru Ikegami · 10 shared papers, 2023–2026 · strength 2.29
   • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
   • Paper Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20340-w↗
   • Paper ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20399-5↗
2. Yoshihiro Shirai · 9 shared papers, 2023–2026 · strength 2.06
   • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
   • Paper Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20340-w↗
   • Paper ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20399-5↗
3. Kenei Furukawa · 9 shared papers, 2023–2026 · strength 2.06
   • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
   • Paper Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20340-w↗
   • Paper ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20399-5↗
4. Koichiro Haruki · 7 shared papers, 2023–2026 · strength 1.63
   • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
   • Paper Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20340-w↗
   • Paper ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20399-5↗
5. Yosuke Igarashi · 6 shared papers, 2023–2026 · strength 1.38
   • Paper Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20340-w↗
   • Paper ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20399-5↗
   • Paper The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resect… DOI 10.1097/mpa.0000000000002416↗
6. Mitsuru Yanagaki · 6 shared papers, 2023–2026 · strength 1.34
   • Paper Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20340-w↗
   • Paper ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20399-5↗
   • Paper The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resect… DOI 10.1097/mpa.0000000000002416↗
7. Masashi Tsunematsu · 6 shared papers, 2023–2026 · strength 1.28
   • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
   • Paper Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pa… DOI 10.21873/cdp.10600↗
   • Paper The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic ca… DOI 10.1007/s00595-025-03050-w↗
8. Ryoga Hamura · 6 shared papers, 2023–2026 · strength 1.28
   • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
   • Paper Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pa… DOI 10.21873/cdp.10600↗
   • Paper The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic ca… DOI 10.1007/s00595-025-03050-w↗
9. Shinji Onda · 6 shared papers, 2023–2026 · strength 1.26
   • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
   • Paper The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resect… DOI 10.1097/mpa.0000000000002416↗
   • Paper The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic ca… DOI 10.1007/s00595-025-03050-w↗
10. Tomohiko Taniai · 5 shared papers, 2023–2026 · strength 1.17
    • Paper Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20340-w↗
    • Paper ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-20399-5↗
    • Paper The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resect… DOI 10.1097/mpa.0000000000002416↗
11. Michinori Matsumoto · 5 shared papers, 2023–2026 · strength 1.01
    • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
    • Paper The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic ca… DOI 10.1007/s00595-025-03050-w↗
    • Paper Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.16968↗
12. Taro Sakamoto · 4 shared papers, 2023–2026 · strength 0.93
    • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
    • Paper Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pa… DOI 10.21873/cdp.10600↗
    • Paper The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resect… DOI 10.1097/mpa.0000000000002416↗
13. Takeshi Gocho · 3 shared papers, 2023–2026 · strength 0.69
    • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
    • Paper Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pa… DOI 10.21873/cdp.10600↗
    • Paper Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically re… DOI 10.1016/j.suronc.2023.101998↗
14. Norimitsu Okui · 2 shared papers, 2026 · strength 0.53
    • Paper Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a m… DOI 10.1007/s00595-026-03416-8↗
    • Paper Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pa… DOI 10.21873/cdp.10600↗
15. Kyohei Abe · 3 shared papers, 2023–2024 · strength 0.51
    • Paper Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.16968↗
    • Paper The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. DOI 10.1177/00031348231204912↗
    • Paper Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically re… DOI 10.1016/j.suronc.2023.101998↗
16. Daisuke Ban · 2 shared papers, 2025–2026 · strength 0.42
    • Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137↗
    • Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095↗
17. Kentaro Umemura · 2 shared papers, 2025–2026 · strength 0.42
    • Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137↗
    • Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095↗
18. Shinji Tanaka · 2 shared papers, 2025–2026 · strength 0.42
    • Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137↗
    • Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095↗
19. Tadashi Uwagawa · 2 shared papers, 2023–2025 · strength 0.38
    • Paper The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic ca… DOI 10.1007/s00595-025-03050-w↗
    • Paper Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically re… DOI 10.1016/j.suronc.2023.101998↗
20. Takashi Aida · 1 shared paper, 2026 · strength 0.26
    • Paper Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pa… DOI 10.21873/cdp.10600↗
21. Yuta Yamada · 1 shared paper, 2026 · strength 0.26
    • Paper Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pa… DOI 10.21873/cdp.10600↗
22. Yuki Mochida · 1 shared paper, 2026 · strength 0.22
    • Paper Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in p… DOI 10.1016/j.ebiom.2026.106137↗
23. Hiroaki Ono · 1 shared paper, 2025 · strength 0.19
    • Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095↗
24. Minoru Tanabe · 1 shared paper, 2025 · strength 0.19
    • Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095↗
25. Yuji Soejima · 1 shared paper, 2025 · strength 0.19
    • Paper PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microen… DOI 10.1158/1541-7786.mcr-24-1095↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.